Dr. Tsewang Tashi, MD

Dr. Tashi practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Tashi's NPI, 1841440674, was assigned on September 29, 2008. Dr. Tashi holds Utah license 8259693-1205.

Dr. Tashi's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Tashi's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Tashi is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Tashi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tashi practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tashi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Tashi's licenses on file in 2 states: Utah and Virginia.

CMS data shows 571 Medicare services from Dr. Tashi across 8 procedure codes in 2024, for 112 Medicare patients. Medicare paid $28,744 for them.

CMS counts 112 Medicare patients who saw Dr. Tashi in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have high blood pressure, and 56% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tashi's median patient age at 73, with 54% women.

In 2024, Dr. Tashi wrote 619 Medicare Part D claims for 83 patients. 66% of them were for generic drugs. CMS names the drug for 491 of them, across 11 drugs with 11 or more claims each, at $3,408,338 in total drug cost. In 2023, CMS named 276 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Tashi for performance year 2024, reported as part of a group. Dr. Tashi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tashi as offering telehealth.

Dmand AI links 30 papers to Dr. Tashi, published from 2010 to 2025. 2025 was the busiest year, with 4. The most frequent topics are Janus Kinase 2, Tibet and Altitude. Dr. Tashi has published most often in Leukemia. Dr. Tashi's most frequent co-authors are Josef T. Prchal, MD, Brandi N. Reeves, MD and Sunil Babu, MD.

Dmand AI links Dr. Tashi to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Chronic-Phase, Mastocytosis, Systemic and Thrombocythemia, Essential.

CMS Open Payments shows 25 general payments to Dr. Tashi from 8 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. Incyte Corporation paid the most, $41,333. It also lists 7 research payments totaling $844 in 2018.